Schwab Health Care Fund
Fund
SWHFX
Price as of:
$25.21
- $0.05
- 0.20%
Primary Theme
fund company
Name
As of 12/07/2023Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
-3.4%
1 yr return
-5.8%
3 Yr Avg Return
5.1%
5 Yr Avg Return
7.7%
Net Assets
$764 M
Holdings in Top 10
39.5%
52 WEEK LOW AND HIGH
$25.3
N/A
N/A
Expenses
OPERATING FEES
Expense Ratio 0.80%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 70.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$0
IRA
N/A
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 12/07/2023Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
SWHFX - Profile
Distributions
- YTD Total Return -3.4%
- 3 Yr Annualized Total Return 5.1%
- 5 Yr Annualized Total Return 7.7%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio 0.76%
- Dividend Yield 0.8%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameSchwab Health Care Fund
-
Fund Family NameSchwab Funds
-
Inception DateJul 21, 2000
-
Shares Outstanding32066968
-
Share ClassOther
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerWei Li
Fund Description
To pursue its goal, the fund primarily invests in equity securities issued by companies in the health care sector. The health care sector may include, for example, pharmaceutical and biotechnology companies, health care facilities operations, medical product
manufacturers and suppliers, medical providers and medical services firms. It is the fund’s policy that under normal circumstances it will invest at least 80% of its net assets (including, for this purpose, any borrowings for investment purposes) in these securities; typically, the actual percentage will be higher. The fund will notify its shareholders at least 60 days before changing this policy. The fund will concentrate its investments in securities of companies in the health care sector.
The fund primarily invests in U.S. companies, but may invest up to 25% of its net assets in the stocks of publicly traded companies located in countries other than the United States. The fund’s international investments will primarily be in stocks issued by companies located in developed market countries; however, it may also invest in stocks issued by companies located in emerging markets. The fund generally does not intend to hedge its exposure to foreign currencies. The fund may invest in companies of all sizes.
The fund actively selects portfolio securities. To aid its U.S. stock selection, the fund uses Schwab Equity Ratings®, a model that assigns ratings to approximately 3,000 of the largest (by market cap) U.S.-traded stocks. To aid its international stock selection, the fund uses Schwab Equity Ratings International®, a model that ranks stocks of foreign companies headquartered and trading in certain foreign countries. In addition to using Schwab Equity Ratings and Schwab Equity Ratings International, the portfolio managers utilize investment data and other analytics to help manage the fund’s portfolio.
Generally, when constructing the portfolio, the portfolio managers invest in stocks that are highly rated by Schwab Equity Ratings or by Schwab Equity Ratings International. As part of the portfolio construction process, the portfolio managers may also purchase lower-rated stocks or stocks that are not rated by Schwab Equity Ratings or by Schwab Equity Ratings International. This investment approach under normal conditions will result in a portfolio that maintains an overall weighting toward highly-rated stocks. For more information on Schwab Equity Ratings and Schwab Equity Ratings International, please see the “More About Schwab’s Research” section in the prospectus.
The fund uses a portfolio optimization process to assist in constructing the portfolio. The portfolio managers use the portfolio optimization process to seek to build a portfolio they believe will provide the optimal balance between risk and expected return, subject to parameters such as the number of stocks desired in the portfolio, the level of portfolio turnover, industry diversification, and volatility considerations.
The fund may invest in derivatives, principally futures contracts, primarily to seek returns on the fund’s otherwise uninvested cash assets. A futures contract is a contract to buy or sell a specific financial instrument at a specified price at a specific future time. By
using these instruments, the fund potentially can offset the impact on its performance of keeping some assets in cash. The fund may invest in exchange-traded funds (ETFs) and stocks of real estate investment trusts (REITs). The fund may also invest in depository receipts evidencing ownership of shares of foreign issuers, including American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs), and European Depositary Receipts (EDRs). The fund also may lend portfolio securities to earn additional income. Any income realized through securities lending may help fund performance.
For temporary defensive purposes during unusual economic or market conditions or for liquidity purposes, the fund may invest up to 100% of its assets in cash, money market instruments, repurchase agreements and other short-term obligations. The fund also may invest in these types of securities or hold cash while looking for suitable investment opportunities. When the fund engages in such activities, it may not achieve its investment objective.
SWHFX - Performance
Return Ranking - Trailing
| Period | SWHFX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -3.4% | -20.7% | 13.9% | 65.03% |
| 1 Yr | -5.8% | -28.5% | 8.9% | 66.26% |
| 3 Yr | 5.1%* | -32.5% | 7.4% | 8.33% |
| 5 Yr | 7.7%* | -9.1% | 13.6% | 42.96% |
| 10 Yr | 9.1%* | 0.1% | 13.3% | 42.99% |
* Annualized
Return Ranking - Calendar
| Period | SWHFX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2022 | -8.4% | -53.9% | 3.2% | 22.44% |
| 2021 | 9.3% | -39.6% | 24.2% | 22.44% |
| 2020 | 1.0% | -13.6% | 178.2% | 92.05% |
| 2019 | 12.5% | 3.8% | 63.8% | 91.11% |
| 2018 | -5.3% | -25.3% | 21.5% | 39.53% |
Total Return Ranking - Trailing
| Period | SWHFX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -3.4% | -20.7% | 13.9% | 65.03% |
| 1 Yr | -5.8% | -28.5% | 8.9% | 66.26% |
| 3 Yr | 5.1%* | -32.5% | 7.4% | 8.33% |
| 5 Yr | 7.7%* | -9.1% | 13.6% | 42.96% |
| 10 Yr | 9.1%* | 0.1% | 13.3% | 42.99% |
* Annualized
Total Return Ranking - Calendar
| Period | SWHFX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2022 | -4.7% | -53.9% | 3.7% | 19.23% |
| 2021 | 23.3% | -33.9% | 26.0% | 5.77% |
| 2020 | 12.9% | -0.7% | 180.6% | 84.11% |
| 2019 | 17.6% | 4.6% | 63.8% | 96.30% |
| 2018 | 4.0% | -20.6% | 22.2% | 29.46% |
NAV & Total Return History
SWHFX - Holdings
Concentration Analysis
| SWHFX | Category Low | Category High | SWHFX % Rank | |
|---|---|---|---|---|
| Net Assets | 764 M | 6.16 M | 45 B | 49.08% |
| Number of Holdings | 77 | 24 | 421 | 59.51% |
| Net Assets in Top 10 | 317 M | 1.61 M | 20.9 B | 53.37% |
| Weighting of Top 10 | 39.55% | 16.4% | 81.7% | 76.07% |
Top 10 Holdings
- UnitedHealth Group Inc 5.79%
- Merck Co Inc 5.00%
- Eli Lilly Co 4.84%
- Johnson Johnson 4.75%
- Novo Nordisk A/S 3.77%
- Amgen Inc 3.39%
- Abbott Laboratories 3.14%
- Roche Holding AG 3.00%
- Cigna Group/The 2.95%
- Vertex Pharmaceuticals Inc 2.91%
Asset Allocation
| Weighting | Return Low | Return High | SWHFX % Rank | |
|---|---|---|---|---|
| Stocks | 99.72% | 90.39% | 106.13% | 23.93% |
| Cash | 0.28% | 0.00% | 30.53% | 82.82% |
| Preferred Stocks | 0.00% | 0.00% | 7.86% | 53.37% |
| Other | 0.00% | -22.99% | 17.97% | 47.85% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 35.44% |
| Bonds | 0.00% | 0.00% | 12.39% | 36.81% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | SWHFX % Rank | |
|---|---|---|---|---|
| Healthcare | 99.35% | 59.26% | 100.00% | 63.92% |
| Basic Materials | 0.65% | 0.00% | 7.16% | 22.78% |
| Utilities | 0.00% | 0.00% | 0.00% | 31.01% |
| Technology | 0.00% | 0.00% | 22.69% | 36.71% |
| Real Estate | 0.00% | 0.00% | 5.89% | 34.81% |
| Industrials | 0.00% | 0.00% | 7.02% | 35.44% |
| Financial Services | 0.00% | 0.00% | 1.60% | 50.00% |
| Energy | 0.00% | 0.00% | 0.00% | 31.01% |
| Communication Services | 0.00% | 0.00% | 9.11% | 34.18% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 39.24% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 35.44% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | SWHFX % Rank | |
|---|---|---|---|---|
| US | 80.91% | 61.78% | 104.41% | 78.53% |
| Non US | 18.81% | 0.00% | 30.85% | 11.66% |
SWHFX - Expenses
Operational Fees
| SWHFX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.80% | 0.08% | 10.48% | 65.64% |
| Management Fee | 0.53% | 0.03% | 1.25% | 22.09% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
| SWHFX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| SWHFX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | 12.20% |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| SWHFX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 70.00% | 0.00% | 238.00% | 84.06% |
SWHFX - Distributions
Dividend Yield Analysis
| SWHFX | Category Low | Category High | SWHFX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.77% | 0.00% | 2.08% | 42.94% |
Dividend Distribution Analysis
| SWHFX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annual | Annually | Quarterly | Annual |
Net Income Ratio Analysis
| SWHFX | Category Low | Category High | SWHFX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | 0.76% | -2.54% | 1.85% | 10.26% |
Capital Gain Distribution Analysis
| SWHFX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Dec 14, 2018 | $0.235 | OrdinaryDividend |
| Dec 08, 2017 | $0.236 | OrdinaryDividend |
| Dec 12, 2016 | $0.205 | OrdinaryDividend |
| Dec 10, 2015 | $0.162 | OrdinaryDividend |
| Dec 09, 2014 | $0.214 | OrdinaryDividend |
| Dec 05, 2013 | $0.186 | OrdinaryDividend |
| Dec 06, 2012 | $0.334 | OrdinaryDividend |
| Dec 22, 2011 | $0.149 | OrdinaryDividend |
| Dec 23, 2010 | $0.187 | OrdinaryDividend |
| Dec 23, 2009 | $0.134 | OrdinaryDividend |
| Dec 23, 2008 | $0.089 | OrdinaryDividend |
| Dec 16, 2002 | $0.033 | OrdinaryDividend |
| Dec 17, 2001 | $0.005 | OrdinaryDividend |
SWHFX - Fund Manager Analysis
Managers
Wei Li
Start Date
Tenure
Tenure Rank
Jun 14, 2013
8.97
9.0%
Wei Li, Ph.D., CFA, Senior Portfolio Manager at Charles Schwab Investment Management Inc. Prior to joining CSIM in 2012, Ms. Li spent more than ten years at Barclays Global Investors (now known as BlackRock, Inc.), where she held a number of positions. From 2001 to 2009, she worked in various roles in the Global Advanced Active group, including portfolio management and quantitative research for both U.S. and international equity markets. After 2009, she worked in the defined contribution research and product development area for almost two years.
Iain Clayton
Start Date
Tenure
Tenure Rank
Feb 27, 2015
7.26
7.3%
Iain Clayton, CFA, FRM, Senior Portfolio Manager, joined Charles Schwab Investment Management Inc in 2013, Mr. Clayton spent more than five years at SSI Investment Management, where he was a portfolio manager and director of quantitative research. In these roles, Mr. Clayton co-managed multiple investment strategies and developed quantitative models and valuation approaches. From 2004 to 2008, he worked as a portfolio manager and director at RCM Capital Management (now known as Allianz Global Investors) and helped manage various equity portfolios and developed fundamental-based stock selection models. Prior to that, he was a vice president at Eureka Investment Advisors for almost three years and also served as a senior quantitative analyst/assistant portfolio manager. He has also worked as a quantitative research analyst at RCM Capital Management.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.84 | 0.25 |